Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: Increased durable cellular immunity with reduced immunodominance

Journal of Immunology

Volumn 175, Issue 11, 2005, Pages 7264-7273

  Moore, Anne C ^a   Gallimore, Awen ^b   Draper, Simon J ^a   Watkins, Katherine R ^a   Gilbert, Sarah C ^a   Hill, Adrian V S ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTIBODY; BACTERIAL ANTIGEN; BCG VACCINE; CD25 ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; RECOMBINANT HEPATITIS B VACCINE; RECOMBINANT PROTEIN; SUBUNIT VACCINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VACCINE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MALARIA; MOUSE; NONHUMAN; PHENOTYPE; POXVIRUS VECTOR; PRIORITY JOURNAL; RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA; T LYMPHOCYTE; VACCINATION; VACCINIA VIRUS; VIRUS RECOMBINANT;

EID: 28244482371     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.11.7264     Document Type: Article

References (50)

1. + T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus. J. Immunol. 172: 3094-3100.
2. McConkey, S. J., W. H. Reece, V. S. Moorthy, D. Webster, S. Dunachie, G. Butcher, J. M. Vuola, T. J. Blanchard, P. Gothard, K. Watkins, et al. 2003. Enhanced T cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9: 729-735.
3. Moorthy, V. S., E. B. Imoukhuede, S. Keating, M. Pinder, D. Webster, M. A. Skinner, S. C. Gilbert, G. Walraven, and A. V. Hill. 2004. Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J. Infect. Dis. 189: 2213-2219.
4. Moorthy, V. S., M. Pinder, W. H. Reece, K. Watkins, S. Atabani, C. Hannan, K. Bojang, K. P. McAdam, J. Schneider, S. Gilbert, and A. V. Hill. 2003. Safety and immunogenicity of DNA/modified vaccinia virus Ankara malaria vaccination in African adults. J. Infect. Dis. 188: 1239-1244.
5. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4: 397-402.
6. +-T cell epitopes from antigen 85A. Infect. Immun. 70: 1623-1626.
7. Goonetilleke, N. P., H. McShane, C. M. Hannan, R. J. Anderson, R. H. Brookes, and A. V. Hill. 2003. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol. 171: 1602-1609.
8. Good, M. F., and D. L. Doolan. 1999. Immune effector mechanisms in malaria. Curr. Opin. Immunol. 11: 412-419.
9. Doolan, D. L., and S. L. Hoffman. 2000. The complexity of protective immunity against liver-stage malaria. J. Immunol. 165: 1453.
10. Plebanski, M., and A. V. Hill. 2000. The immunology of malaria infection. Curr. Opin. Immunol. 12: 437-441.
11. Moore, A. C., and A. V. Hill. 2004. Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunol. Rev. 199: 126-143.
12. Vuola, J. M., S. Keating, D. P. Webster, T. Berthoud, S. Dunachie, S. C. Gilbert, and A. V. Hill. 2005. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J. Immunol. 174: 449-455.
13. Bejon, P., L. Andrews, R. F. Andersen, S. Dunachie, D. Webster, M. Walther, S. C. Gilbert, T. Peto, and A. V. Hill. 2005. Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J. Infect. Dis. 191: 619-626.
14. + regulatory T cells that express Toll-like receptors. J. Exp. Med. 197: 397-401.
15. Bluestone, J. A., and A. K. Abbas. 2003. Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 3: 253-257.
16. Mittrucker, H. W., and S. H. Kaufmann. 2004. Mini-review: regulatory T cells and infection: suppression revisited. Eur. J. Immunol. 34: 306-312.
17. + T cells with IFN-γ-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J. Immunol. 171: 5931-5939.
18. + regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur. J. Immunol. 32: 3267-3275.
19. + regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun. 2: 1.
20. Yang, Y., C. T. Huang, X. Huang, and D. M. Pardoll. 2004. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat. Immunol. 5: 508-515.
21. + T cell responses against herpes simplex virus type 1. J. Virol. 78: 13082-13089.
22. + T cell responses. J. Exp. Med. 196: 1585-1592.
23. + regulatory T cells control the severity of viral immunoinflammatory lesions. J. Immunol. 172: 4123-4132.
24. + T cell responses. J. Exp. Med. 198: 889-901.
25. Gilbert, S. C., J. Schneider, C. M. Hannan, J. T. Hu, M. Plebanski, R. Sinden, and A. V. Hill. 2002. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 20: 1039-1045.
26. + T cell determinants to enable rational design and characterization of smallpox vaccines. J. Exp. Med. 201: 95-104.
27. Romero, P., J. L. Maryanski, G. Corradin, R. S. Nussenzweig, V. Nussenzweig, and F. Zavala. 1989. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 341: 323-326.
28. Barouch, D. H., J. Kunstman, M. J. Kuroda, J. E. Schmitz, S. Santra, F. W. Peyerl, G. R. Krivulka, K. Beaudry, M. A. Lifton, D. A. Gorgone, et al. 2002. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415: 335-339.
29. Ockenhouse, C. F., P. F. Sun, D. E. Lanar, B. T. Wellde, B. T. Hall, K. Kester, J. A. Stoute, A. Magill, U. Krzych, L. Farley, et al. 1998. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J. Infect. Dis. 177: 1664-1673.
30. Prieur, E., S. Gilbert, J. Schneider, A. C. Moore, E. Sheu, N. Goonetilleke, K. J. Robson, and A. Hill. 2004. A Plasmodium falciparum candidate vaccine based on a six antigen polyprotein encoded by recombinant poxviruses. Proc. Natl. Acad. Sci. USA 101: 290-295.
31. + T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation. Int. Immunol. 12: 1145-1155.
32. high regulatory cells in human peripheral blood. J. Immunol. 167: 1245-1253.
33. Yewdell, J. W., and J. R. Bennink. 1999. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17: 51-88.
34. Koup, R. A. 1994. Virus escape from CTL recognition. J. Exp. Med. 180: 779-782.
35. Goulder, P. J., C. Brander, Y. Tang, C. Tremblay, R. A. Colbert, M. M. Addo, E. S. Rosenberg, T. Nguyen, R. Allen, A. Trocha, et al. 2001. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 412: 334-338.
36. + T cell responses induced by direct priming and cross-priming and moderate immunodominance disparities. J. Immunol. 174: 3344-3351.
37. + T cells. Proc. Natl. Acad. Sci. USA 99: 8832-8837.
38. + memory T cells by opposing cytokines. Science 288: 675-678.
39. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22: 531-562.
40. + immunoregulatory T cells is antigen nonspecific. J. Immunol. 164: 183-190.
41. Lowenthal, J. W., P. Corthesy, C. Tougne, R. Lees, H. R. MacDonald, and M. Nabholz. 1985. High and low affinity IL-2 receptors: analysis by IL-2 dissociation rate and reactivity with monoclonal anti-receptor antibody PC61. J. Immunol. 135: 3988-3994.
42. Jankovic, D. L., A. Rebollo, A. Kumar, M. Gibert, and J. Theze. 1990. IL-2-dependent proliferation of murine T cells requires expression of both the p55 and p70 subunits of the IL-2 receptor. J. Immunol. 145: 4136-4144.
43. Blattman, J. N., J. M. Grayson, E. J. Wherry, S. M. Kaech, K. A. Smith, and R. Ahmed. 2003. Therapeutic use of IL-2 to enhance antiviral T cell responses in vivo. Nat. Med. 9: 540-547.
44. + T cells increases the size of the acute antiviral response and of the resulting memory T cell pool. J. Immunol. 169: 4990-4997.
45. Malek, T. R., and A. L. Bayer. 2004. Tolerance, not immunity, crucially depends on IL-2. Nat. Rev. Immunol. 4: 665-674.
46. + regulatory T cells fail to undergo chromatin remodeling across the proximal promoter region of the IL-2 gene. J. Immunol. 173: 4994-5001.
47. + T cells on Plasmodium berghei NK65 infection in BALB/c mice. Int. J. Parasitol. 33: 175-183.
48. Adu, D., P. Cockwell, N. J. Ives, J. Shaw, and K. Wheatley. 2003. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ 326: 789.
49. Nussenblatt, R. B., D. J. Thompson, Z. Li, J. S. Peterson, R. R. Robinson, R. S. Shames, S. Nagarajan, M. T. Tang, M. Mailman, G. Velez, et al. 2003. Humanized anti-interleukin-2 (IL-2) receptor α therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J. Autoimmun. 21: 283-293.
50. Phan, G. Q., J. C. Yang, R. M. Sherry, P. Hwu, S. L. Topalian, D. J. Schwartzentruber, N. P. Restifo, L. R. Haworth, C. A. Seipp, L. J. Freezer, et al. 2003. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 100: 8372-8377.